RT @sumitshahMD: Addition of IO + chemotherapy did not improve outcomes in 1st line metastatic urothelial. PDL1 status an inconsistent biom…
RT @DrChoueiri: 10/ The phase 3 KEYNOTE-361 trial showing that the addition of pembrolizumab to first-line platinum-based chemotherapy does…
➓ دراسة KEYNOTE-361. دراسة سلبية لم تظهر أي فائدة لإضافة pembrolizumab إلى الخط الأول بالعلاج الكيمائي بالبلاتينيوم في علاج سرطان المثانة المنتشر https://t.co/HFDmL3q0tH
RT @DrChoueiri: 10/ The phase 3 KEYNOTE-361 trial showing that the addition of pembrolizumab to first-line platinum-based chemotherapy does…
RT @DrChoueiri: 10/ The phase 3 KEYNOTE-361 trial showing that the addition of pembrolizumab to first-line platinum-based chemotherapy does…
RT @DrChoueiri: 10/ The phase 3 KEYNOTE-361 trial showing that the addition of pembrolizumab to first-line platinum-based chemotherapy does…
10/ The phase 3 KEYNOTE-361 trial showing that the addition of pembrolizumab to first-line platinum-based chemotherapy does not improve PFS/OS of patients with mUC @tompowles1 @AlvaAjjai @UMRogelCancer @y_loriot @GustaveRoussy https://t.co/uMOUI7GYxD htt
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
Disappointing… My money is on the chemotherapy regimen used
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
RT @apolo_andrea: KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs…
KEYNOTE-361 phase 3 trial randomized N=1010 metastatic #BladderCancer pts 1L to pembro vs chemo (Cis/gem or carbo/gem) vs pembro+chemo: Pembro+chemo vs chemo did not improve PFS (8 vs 7 mo) or OS (17 vs 14 mo HR 0.86) https://t.co/TAngjwX31Z @TheLancetOnco
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @TheLancetOncol: In the July issue: KEYNOTE-361 - #Pembrolizumab alone or combined with #chemotherapy versus chemotherapy as first-line…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
Addition of IO + chemotherapy did not improve outcomes in 1st line metastatic urothelial. PDL1 status an inconsistent biomarker in bladder. Will see how this plays out in neoadjuvant setting.
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
RT @tompowles1: Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cance…
Keynote 361 out this week. Pembro alone or combined with chemo in UC. It’s unclear why we couldn’t reproduce the lung cancer data. ICI activity is specific to tumor type +/- type of chemo used. The PDL1 CPS biomarker was more prognostic than predictive. h
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial https://t.co/dopFsJis1M #hvhebron #onco @TheLancetOncol
RT @TheLancetOncol: In the July issue: KEYNOTE-361 - #Pembrolizumab alone or combined with #chemotherapy versus chemotherapy as first-line…
RT @TheLancetOncol: In the July issue: KEYNOTE-361 - #Pembrolizumab alone or combined with #chemotherapy versus chemotherapy as first-line…
RT @TheLancetOncol: In the July issue: KEYNOTE-361 - #Pembrolizumab alone or combined with #chemotherapy versus chemotherapy as first-line…
RT @TheLancetOncol: In the July issue: KEYNOTE-361 - #Pembrolizumab alone or combined with #chemotherapy versus chemotherapy as first-line…
RT @TheLancetOncol: In the July issue: KEYNOTE-361 - #Pembrolizumab alone or combined with #chemotherapy versus chemotherapy as first-line…
In the July issue: KEYNOTE-361 - #Pembrolizumab alone or combined with #chemotherapy versus chemotherapy as first-line therapy for advanced #urothelialcarcinoma: a randomised, open-label, phase 3 trial #gucsm #bladdercancer https://t.co/nGaojurxGx
RT @NatRevClinOncol: In the phase III KEYNOTE-361 trial of pembrolizumab +/- chemotherapy vs chemotherapy as first-line therapy for advanc…
【RCT】未治療の局所進行、切除不能または転移性の尿路上皮癌患者に対する化学療法へのペムブロリズマブの追加は、追加なしと比較して、無増悪生存期間および全生存期間を延長させなかった。 #ペ読 https://t.co/Jv2Ra3xkcg
RT @m0370: ESMO2020で出てたやつか。KEYNOTE-361、尿路上皮癌の一次治療でGEM+CDDPかGEM+CBDCAへのペムブロリズマブ上乗せはPD-L1のCPS>10でもPFS・OSとも延長示さず。これ、KEYNOTE特有のαを分割しまくるデザインだけど、…
RT @m0370: ESMO2020で出てたやつか。KEYNOTE-361、尿路上皮癌の一次治療でGEM+CDDPかGEM+CBDCAへのペムブロリズマブ上乗せはPD-L1のCPS>10でもPFS・OSとも延長示さず。これ、KEYNOTE特有のαを分割しまくるデザインだけど、…
RT @m0370: ESMO2020で出てたやつか。KEYNOTE-361、尿路上皮癌の一次治療でGEM+CDDPかGEM+CBDCAへのペムブロリズマブ上乗せはPD-L1のCPS>10でもPFS・OSとも延長示さず。これ、KEYNOTE特有のαを分割しまくるデザインだけど、…
RT @NatRevClinOncol: In the phase III KEYNOTE-361 trial of pembrolizumab +/- chemotherapy vs chemotherapy as first-line therapy for advanc…
RT @NatRevClinOncol: In the phase III KEYNOTE-361 trial of pembrolizumab +/- chemotherapy vs chemotherapy as first-line therapy for advanc…
RT @NatRevClinOncol: In the phase III KEYNOTE-361 trial of pembrolizumab +/- chemotherapy vs chemotherapy as first-line therapy for advanc…
ESMO2020で出てたやつか。KEYNOTE-361、尿路上皮癌の一次治療でGEM+CDDPかGEM+CBDCAへのペムブロリズマブ上乗せはPD-L1のCPS>10でもPFS・OSとも延長示さず。これ、KEYNOTE特有のαを分割しまくるデザインだけど、それが裏目に出てるのよな。全患者のPFSかOSにαを集めてたらポジティブになるはずだった。
In the phase III KEYNOTE-361 trial of pembrolizumab +/- chemotherapy vs chemotherapy as first-line therapy for advanced-stage urothelial carcinoma, PFS and OS were not significantly different, even in the group with a PD-L1 CPS of >10: https://t.co/GgT
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial ESTUDIO NEGATIVO https://t.co/4fFJe1L2rI
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial https://t.co/A4shciNITq #hvhebron #onco @TheLancetOncol
RT @tompowles1: Pembro +chemo isn’t additive in UC and the trial was -ve. Data suggests some pembro activity after the chemo stopped. Chemo…